{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:03:00Z","timestamp":1780549380443,"version":"3.54.1"},"reference-count":211,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Although previously B cells had been underestimated in comparison to T cells in their role in autoimmunity, now, their impact is well established. Via secretion of autoantibodies, presentation of autoantigens, regulation of antigen processing and presentation, and release of inflammatory cytokines, B cells can mediate cytotoxicity and lead to organ damage. B cell depletion via CD20 targeting effectively eliminates B cells in the blood and primary lymph organs and has found an effective role in the treatment of both rheumatological and neurological diseases. The neonatal Fc receptor (FcRn) is a key component of immune regulation that prevents IgG (produced by B cells) from degradation by lysosomes, sending it back into the extracellular compartment, thereby extending its half-life. This abundance of pathogenic IgG can lead to the development of autoimmune disease. The interplay between these two mechanisms of autoimmunity provides the great potential for combination therapy to reduce existent pathogenic IgG as well as prevent the production of new autoantibodies, though further investigation is needed to determine the risks, particularly of infection. This paper will explore existing B cell depleting treatments and FcRn inhibitors, and consider the potential impact for autoimmune disease as well as for the treatment of atherosclerosis.<\/jats:p>","DOI":"10.3390\/life16060923","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:37:29Z","timestamp":1780544249000},"page":"923","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis"],"prefix":"10.3390","volume":"16","author":[{"given":"Jenny Lue","family":"Solomon","sequence":"first","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-3148","authenticated-orcid":false,"given":"Anjali","family":"Dubbaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-2183","authenticated-orcid":false,"given":"Ankita","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2334-907X","authenticated-orcid":false,"given":"Elise","family":"Belilos","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua De","family":"Leon","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2732-8095","authenticated-orcid":false,"given":"Steven E.","family":"Carsons","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"additional","affiliation":[{"name":"Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"},{"name":"Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Malekmohammad, K., Bezsonov, E.E., and Rafieian-Kopaei, M. (2021). Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.707529"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-3754-8_1","article-title":"Immune Homeostasis: A Novel Example of Teamwork","volume":"2782","author":"Kumar","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41577-024-01087-5","article-title":"How oxygenation shapes immune responses: Emerging roles for physioxia and pathological hypoxia","volume":"25","author":"Mirchandani","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/imr.12749","article-title":"Cell circuits and niches controlling B cell development","volume":"289","author":"Zehentmeier","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rastogi, I., Jeon, D., Moseman, J.E., Muralidhar, A., Potluri, H.K., and McNeel, D.G. (2022). Role of B cells as antigen presenting cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.954936"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e51720","DOI":"10.1002\/eji.202451720","article-title":"Self-Antigens Select B Cells: A New Perspective on B Cell Selection and Function","volume":"55","author":"Aoun","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gomez-Manriquez, J., Hernandez-Bello, J., Munoz-Valle, J.F., Sifuentes-Franco, S., Graciano-Machuca, O., and Morales-Nunez, J.J. (2025). B cell development: Transcriptional regulation and immunological mechanisms in homeostasis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1593338"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Raza, I.G.A., and Clarke, A.J. (2021). B Cell Metabolism and Autophagy in Autoimmunity. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.681105"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., and Anzaghe, M. (2021). The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168947"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cell.2019.03.037","article-title":"Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10","volume":"177","author":"Rojas","year":"2019","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sanz, I., Wei, C., Jenks, S.A., Cashman, K.S., Tipton, C., Woodruff, M.C., Hom, J., and Lee, F.E. (2019). Challenges and Opportunities for Consistent Classification of Human B Cell and Plasma Cell Populations. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02458"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pyzik, M., Sand, K.M.K., Hubbard, J.J., Andersen, J.T., Sandlie, I., and Blumberg, R.S. (2019). The Neonatal Fc Receptor (FcRn): A Misnomer?. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01540"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12972","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Qi, T., and Cao, Y. (2021). In Translation: FcRn across the Therapeutic Spectrum. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063048"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc Receptor\u2014Biology and Therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yang, C.W., Xia, T., Tan, Q., Jie, L.G., Lou, A.J., Li, X.X., Maitiyaer, M., Huang, W.H., Zheng, Y., and Yu, S.L. (2025). From promise to practice: Evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1656937"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/imr.12331","article-title":"The multiple facets of FcRn in immunity","volume":"268","author":"Stapleton","year":"2015","journal-title":"Immunol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.placenta.2019.02.012","article-title":"Expression of the neonatal Fc-receptor in placental-fetal endothelium and in cells of the placental immune system","volume":"78","author":"Kiskova","year":"2019","journal-title":"Placenta"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mimoun, A., Delignat, S., Peyron, I., Daventure, V., Lecerf, M., Dimitrov, J.D., Kaveri, S.V., Bayry, J., and Lacroix-Desmazes, S. (2020). Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00810"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wilcox, C.R., Holder, B., and Jones, C.E. (2017). Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01294"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"271363","DOI":"10.1155\/2008\/271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin. Dev. Immunol."},{"key":"ref_27","first-page":"1637","article-title":"FcRn inhibitors: A novel option for the treatment of myasthenia gravis","volume":"18","author":"Zhu","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108910","DOI":"10.1016\/j.clineuro.2025.108910","article-title":"Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta-analysis","volume":"254","author":"Akhtar","year":"2025","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.179.5.2999","article-title":"NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences","volume":"179","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Qian, S., Li, C., Liu, X., Jia, X., Xiao, Y., and Li, Z. (2021). Activation of the JNK\/MAPK Signaling Pathway by TGF-beta1 Enhances Neonatal Fc Receptor Expression and IgG Transcytosis. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040879"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: Pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103760","DOI":"10.1016\/j.autrev.2025.103760","article-title":"Immunomodulation for accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus","volume":"24","author":"Bartoloni","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.07.016","article-title":"Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis","volume":"128","author":"Drosos","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/ATVBAHA.113.302667","article-title":"Circulating CD40+ and CD86+ B cell subsets demonstrate opposing associations with risk of stroke","volume":"34","author":"Mantani","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Jiang, Y., Zou, Y., Fan, Y., Feng, P., Fu, X., Li, K., Zhang, J., Dong, Y., and Yan, S. (2023). Peripheral blood CD19 positive B lymphocytes increase after ischemic stroke and correlate with carotid atherosclerosis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1308041"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4103\/1673-5374.360345","article-title":"Bystanders or not? Microglia and lymphocytes in aging and stroke","volume":"18","author":"Nguyen","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_37","first-page":"1532832","article-title":"The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis","volume":"2016","author":"Roshan","year":"2016","journal-title":"Int. J. Inflamm."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ma, S.D., Mussbacher, M., and Galkina, E.V. (2021). Functional Role of B Cells in Atherosclerosis. Cells, 10.","DOI":"10.3390\/cells10020270"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zahr, T., Zhang, K., Huang, S., Xue, C., Yu, L., Yu, Z., Li, B., Liang, D., Wang, Q., and Shadrina, M. (2026). IgG Propels Atherosclerosis by Noncanonically Activating Macrophages. bioRxiv.","DOI":"10.64898\/2026.03.13.711718"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.2147\/DDDT.S527687","article-title":"Rheumatoid Arthritis Therapy Based on B Cells","volume":"19","author":"Liang","year":"2025","journal-title":"Drug Des. Devel Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Jang, S., Kwon, E.J., and Lee, J.J. (2022). Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020905"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wu, F., Gao, J., Kang, J., Wang, X., Niu, Q., Liu, J., and Zhang, L. (2021). B Cells in Rheumatoid Arthritis: Pathogenic Mechanisms and Treatment Prospects. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.750753"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kubota, T. (2023). An Emerging Role for Anti-DNA Antibodies in Systemic Lupus Erythematosus. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202310.2067.v1"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, R., Liang, Q., Ni, S., Yang, M., Qiu, L., Ji, J., Gu, Z., and Dong, C. (2025). Organ-based characterization of B cells in patients with systemic lupus erythematosus. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1509033"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Domeier, P.P., and Rahman, Z.S.M. (2021). Regulation of B Cell Responses in SLE by Three Classes of Interferons. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910464"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/intimm\/dxae058","article-title":"The role of polyreactive memory B cells in systemic lupus erythematosus","volume":"37","author":"Fujio","year":"2025","journal-title":"Int. Immunol."},{"key":"ref_48","first-page":"271","article-title":"When B cells break bad: Development of pathogenic B cells in Sjogren\u2019s syndrome","volume":"38","author":"Reed","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sjogren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Du, W., Han, M., Zhu, X., Xiao, F., Huang, E., Che, N., Tang, X., Zou, H., Jiang, Q., and Lu, L. (2021). The Multiple Roles of B Cells in the Pathogenesis of Sjogren\u2019s Syndrome. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.684999"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/25785826.2024.2407224","article-title":"The immunological pathogenesis of IgG4-related disease categorized by clinical characteristics","volume":"48","author":"Akiyama","year":"2025","journal-title":"Immunol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(17)30471-4","article-title":"IgG4-related disease of the central and peripheral nervous systems","volume":"17","author":"AbdelRazek","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2018.10.006","article-title":"The role of B cells in multiple sclerosis: Current and future therapies","volume":"339","author":"Negron","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"van Langelaar, J., Rijvers, L., Smolders, J., and van Luijn, M.M. (2020). B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00760"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"106756","DOI":"10.1016\/j.msard.2025.106756","article-title":"Diagnostic evolution in multiple sclerosis: A narrative review of the McDonald criteria from 2001 to 2024","volume":"104","author":"Agrawal","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Cai, M.T., Yang, F., Zhou, J.P., Fang, W., Shen, C.H., Zhang, Y.X., and Ding, M.P. (2020). IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01799"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"105905","DOI":"10.1016\/j.ebiom.2025.105905","article-title":"Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis","volume":"120","author":"Deisenhammer","year":"2025","journal-title":"EBioMedicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B Cells in Multiple Sclerosis and Related Disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hausser-Kinzel, S., and Weber, M.S. (2019). The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00201"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Rodriguez-Mogeda, C., Rodriguez-Lorenzo, S., Attia, J., van Horssen, J., Witte, M.E., and de Vries, H.E. (2022). Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis. Biomolecules, 12.","DOI":"10.3390\/biom12060800"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1172\/JCI63842","article-title":"B cell exchange across the blood-brain barrier in multiple sclerosis","volume":"122","author":"Kuo","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lassmann, H. (2018). Pathogenic Mechanisms Associated with Different Clinical Courses of Multiple Sclerosis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03116"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/art.43316","article-title":"Mechanisms of B Cell Tolerance in Health and Autoimmunity","volume":"78","author":"Ponnan","year":"2026","journal-title":"Arthritis Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: Advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e70436","DOI":"10.1002\/ctm2.70436","article-title":"Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis","volume":"15","author":"Li","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/25785826.2020.1724756","article-title":"Antigen specific B cells in myasthenia gravis patients","volume":"43","author":"Takata","year":"2020","journal-title":"Immunol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Fichtner, M.L., Jiang, R., Bourke, A., Nowak, R.J., and O\u2019Connor, K.C. (2020). Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00776"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: An Immunopathological Study in 1035 Cases and a Critical Review","volume":"52","author":"Truffault","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/med-25-12","article-title":"Thymic hyperplasia in myasthenia gravis: A narrative review","volume":"9","author":"Sikorski","year":"2025","journal-title":"Mediastinum"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yan, Y., Patino, D.A., Zhao, Y., Wu, X., Budinger, G.R.S., and Bharat, A. (2025). Myasthenia thymus reprograms class-switched B cells into BAFF-dependent survivors. bioRxiv.","DOI":"10.1101\/2025.09.19.677075"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.nmd.2017.06.012","article-title":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","volume":"27","author":"Muto","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","article-title":"Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis","volume":"18","author":"Bresch","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ochi, H., Nakamura, S., and Nakahara, J. (2025). B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: Rationale, evidence, and challenges. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1635989"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Correale","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12974-021-02375-w","article-title":"Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder","volume":"19","author":"Hoshino","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Dai, S., Pang, R., Qin, L., Zhang, M., Liu, H., Wang, X., Zhang, J., Peng, G., and Wang, Y. (2024). Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1322125"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Huang, W., Lin, R., Zeng, X., Wang, H., and Yan, J. (2025). Decoding paraneoplastic neuromyelitis optica: A multi-omics investigation of tumor-driven T and B cell dynamics. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1665688"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e2121804119","DOI":"10.1073\/pnas.2121804119","article-title":"Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders","volume":"119","author":"Damato","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/brain\/awad373","article-title":"Interferon-gamma controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder","volume":"147","author":"Arellano","year":"2024","journal-title":"Brain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e70151","DOI":"10.1002\/psp4.70151","article-title":"B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic Diseases","volume":"15","author":"Nakada","year":"2026","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hofmann, K., Clauder, A.K., and Manz, R.A. (2018). Targeting B Cells and Plasma Cells in Autoimmune Diseases. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00835"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.biopha.2018.11.121","article-title":"The applications of anti-CD20 antibodies to treat various B cells disorders","volume":"109","author":"Payandeh","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.2009.03977.x","article-title":"Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases","volume":"157","author":"Hu","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/17843286.2018.1521904","article-title":"Rituximab in systemic autoimmune rheumatic diseases: Indications and practical use","volume":"74","author":"Berghen","year":"2019","journal-title":"Acta Clin. Belg."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: A longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/acr2.11074","article-title":"Patterns of B Cell Repletion Following Rituximab Therapy in a Pediatric Rheumatology Cohort","volume":"1","author":"Mitchell","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102089","DOI":"10.1016\/j.isci.2021.102089","article-title":"Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways","volume":"24","author":"Edelmann","year":"2021","journal-title":"iScience"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.41608","article-title":"The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model","volume":"73","author":"Marinov","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Wu, W., Wang, J., and Chen, S. (2025). Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: A report of 16 cases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1624234"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Breakell, T., Tacke, S., Schropp, V., Zetterberg, H., Blennow, K., Urich, E., and Kuerten, S. (2020). Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186864"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102643","DOI":"10.1016\/j.conb.2022.102643","article-title":"Targeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders","volume":"77","author":"Liyanage","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"de Seze, J., Maillart, E., Gueguen, A., Laplaud, D.A., Michel, L., Thouvenot, E., Zephir, H., Zimmer, L., Biotti, D., and Liblau, R. (2023). Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1004795"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: A Review in Multiple Sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: Current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Mariottini, A., Muraro, P.A., and Lunemann, J.D. (2022). Antibody-mediated cell depletion therapies in multiple sclerosis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.953649"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"ref_111","first-page":"20552173211069359","article-title":"Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions","volume":"8","author":"Alvarez","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"102787","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s13760-024-02572-3","article-title":"Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: A single-center experience for 4-year follow-up","volume":"124","author":"Erdogan","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Florou, D., Katsara, M., Feehan, J., Dardiotis, E., and Apostolopoulos, V. (2020). Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sci., 10.","DOI":"10.3390\/brainsci10100758"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.27143","article-title":"Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann. Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","article-title":"The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function","volume":"39","author":"Cree","year":"2025","journal-title":"CNS Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1111\/bcp.15332","article-title":"Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders","volume":"88","author":"Yan","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chen, D., Gallagher, S., Monson, N.L., Herbst, R., and Wang, Y. (2016). Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med., 5.","DOI":"10.3390\/jcm5120107"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management","volume":"271","author":"Kumpfel","year":"2024","journal-title":"J. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e45293","DOI":"10.1097\/MD.0000000000045293","article-title":"Inebilizuma treatment for acute serum AQP4\u2014IgG neuromyelitis optica: Case report","volume":"104","author":"Zhu","year":"2025","journal-title":"Medicine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"104321","DOI":"10.1016\/j.ebiom.2022.104321","article-title":"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial","volume":"86","author":"Bennett","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1002\/acn3.51911","article-title":"Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism","volume":"10","author":"Kim","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult. Scler."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u22654 years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2022.6815","article-title":"Association of COVID-19 Vaccination with Breakthrough Infections and Complications in Patients with Cancer","volume":"9","author":"Gong","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e47121b1","DOI":"10.1097\/01.HS9.0000973136.47121.b1","article-title":"P1565: Incidence of Pneumocystis Jorivecii Pneumonia in Patients with B-Lneage Lymphoma Reeiving Chemotherapy Containing Rituximab","volume":"7","author":"Liang","year":"2023","journal-title":"Hemasphere"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/art.42541","article-title":"Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients with Rheumatic Diseases Receiving Rituximab","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: A rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J. NeuroVirology"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Scavone, C., Cagnotta, C., Sportiello, L., Maniscalco, G.T., Ragone, A., Frasca, M., Rinaldi, B., and Capuano, A. (2025). Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: A systematic review and meta-analysis of observational studies. Expert Opin. Drug Saf., 1\u201321. Epub ahead of print.","DOI":"10.1080\/14740338.2025.2574668"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/1756-185X.13596","article-title":"Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis","volume":"22","author":"Shi","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/acr.25222","article-title":"Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA-Associated Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide","volume":"76","author":"Nettleton","year":"2024","journal-title":"Arthritis Care Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Charoenrit, P., Niparuck, P., and Rotjanapan, P. (2026). Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0344273"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: A 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Sabbah","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yjmcc.2013.04.023","article-title":"Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction","volume":"62","author":"Yan","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/08916934.2017.1280669","article-title":"Opposing roles of B lymphocyte subsets in atherosclerosis","volume":"50","author":"Kyaw","year":"2017","journal-title":"Autoimmunity"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1084\/jem.20100155","article-title":"B cell depletion reduces the development of atherosclerosis in mice","volume":"207","author":"Herbin","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.1000033","article-title":"Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis","volume":"185","author":"Kyaw","year":"2010","journal-title":"J. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/nm.3284","article-title":"B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction","volume":"19","author":"Zouggari","year":"2013","journal-title":"Nat. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e005747","DOI":"10.1161\/JAHA.117.005747","article-title":"High Levels of (Un)Switched Memory B Cells Are Associated with Better Outcome in Patients with Advanced Atherosclerotic Disease","volume":"6","author":"Meeuwsen","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Veh, J., Ludwig, C., Schrezenmeier, H., and Jahrsdorfer, B. (2024). Regulatory B Cells-Immunopathological and Prognostic Potential in Humans. Cells, 13.","DOI":"10.3390\/cells13040357"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00395-021-00886-4","article-title":"Regulatory B cells improve ventricular remodeling after myocardial infarction by modulating monocyte migration","volume":"116","author":"Jiao","year":"2021","journal-title":"Basic Res. Cardiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"21673","DOI":"10.1073\/pnas.1911464116","article-title":"IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction","volume":"116","author":"Wu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","first-page":"2664","article-title":"The healing myocardium mobilizes a distinct B-cell subset through a CXCL13-CXCR5-dependent mechanism","volume":"117","author":"Heinrichs","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jacbts.2021.01.006","article-title":"B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications","volume":"6","author":"Pattarabanjird","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Kyaw, T., Tay, C., Hosseini, H., Kanellakis, P., Gadowski, T., MacKay, F., Tipping, P., Bobik, A., and Toh, B.H. (2012). Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029371"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kyaw, T., Cui, P., Tay, C., Kanellakis, P., Hosseini, H., Liu, E., Rolink, A.G., Tipping, P., Bobik, A., and Toh, B.H. (2013). BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-\/-) mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060430"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.117.032790","article-title":"B Cell-Activating Factor Neutralization Aggravates Atherosclerosis","volume":"138","author":"Tsiantoulas","year":"2018","journal-title":"Circulation"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s10753-021-01455-6","article-title":"Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention","volume":"44","author":"Reiss","year":"2021","journal-title":"Inflammation"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Matsunaga, K., Harada, M., Suizu, J., Oishi, K., Asami-Noyama, M., and Hirano, T. (2020). Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103078"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2025.05.006","article-title":"Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer","volume":"113","author":"Delk","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00392-023-02291-4","article-title":"Cardiovascular events risk in patients with systemic autoimmune diseases: A prognostic systematic review and meta-analysis","volume":"113","author":"Gonzalez","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/rheumatology\/keae192","article-title":"Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment","volume":"64","author":"Dedemadi","year":"2025","journal-title":"Rheumatology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Zhou, Y., and Jiang, S. (2023). Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker. Pathogens, 12.","DOI":"10.3390\/pathogens12060817"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Fu, J., Zheng, X., Ma, X., Qu, Q., Cui, W., Mao, X., Fu, W., and Lyv, H. (2026). Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod. BMC Neurol., 26.","DOI":"10.1186\/s12883-026-04726-7"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/acn3.70283","article-title":"In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis","volume":"13","author":"Jin","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/bcp.13270","article-title":"Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients","volume":"83","author":"Lioger","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2361585","DOI":"10.1080\/19420862.2024.2361585","article-title":"Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn","volume":"16","author":"Reusch","year":"2024","journal-title":"MAbs"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Abdeldaim, D.T., and Schindowski, K. (2023). Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15102402"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1080\/19420862.2019.1633883","article-title":"Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life","volume":"11","author":"Mackness","year":"2019","journal-title":"MAbs"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"156971","DOI":"10.1016\/j.cyto.2025.156971","article-title":"FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes","volume":"193","author":"Nilforoushzadeh","year":"2025","journal-title":"Cytokine"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41541-024-00854-8","article-title":"FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines","volume":"9","author":"Macri","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1002\/cam4.3067","article-title":"The neonatal Fc receptor in cancer FcRn in cancer","volume":"9","author":"Brachet","year":"2020","journal-title":"Cancer Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"ref_180","first-page":"1103","article-title":"Ultrastructural analysis of enamel formation during in vitro development using chemically-defined medium","volume":"1","author":"Bringas","year":"1987","journal-title":"Scanning Microsc."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Howard, J.F., Bril, V., Vu, T., Karam, C., Peric, S., De Bleecker, J.L., Murai, H., Meisel, A., Beydoun, S.R., and Pasnoor, M. (2023). Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): Interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1284444"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"578963","DOI":"10.1016\/j.jneuroim.2026.578963","article-title":"Sequential efgartigimod-rituximab therapy in autoimmune nodopathy: A feasibility report on shortening the washout interval for B-cell depletion","volume":"418","author":"Sun","year":"2026","journal-title":"J. Neuroimmunol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","article-title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases","volume":"21","author":"Gwathmey","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Yasuda, M., Uzawa, A., Handa, H., Ogaya, E., Kurumada, K., Takasaka, K., Mori, M., and Kuwabara, S. (2026). Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis. Naunyn Schmiedebergs Arch. Pharmacol., Epub ahead of print.","DOI":"10.1007\/s00210-026-05274-0"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","article-title":"Rozanolixizumab for Myasthenia Gravis: A breakthrough treatment and future prospects","volume":"17","author":"Matic","year":"2025","journal-title":"Immunotherapy"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/22143602241305511","article-title":"Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions","volume":"12","author":"Bril","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ard.2025.09.011","article-title":"Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: A proof-of-concept study","volume":"85","author":"Carlucci","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00415-025-12958-9","article-title":"Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: The randomized open-label extension MG0004 study","volume":"272","author":"Bril","year":"2025","journal-title":"J. Neurol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1136\/bmjno-2023-000536","article-title":"Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: Rationale and study design of a phase 3 clinical trial","volume":"6","author":"Benatar","year":"2024","journal-title":"BMJ Neurol. Open"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"103719","DOI":"10.1016\/j.autrev.2024.103719","article-title":"FcRn inhibitors: Transformative advances and significant impacts on IgG-mediated autoimmune diseases","volume":"24","author":"Zhu","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Gable, K.L., and Guptill, J.T. (2019). Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.03052"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2461191","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"MAbs"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Bussel, J., Stegmann, B., Baker, P., Oey, A., Jiang, Y., Zaha, R., Van Valkenburgh, H., and Keshinro, B. (2025). Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. Am. J. Perinatol., Epub ahead of print.","DOI":"10.1055\/a-2753-9323"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Leu, J.H., Vermeulen, A., Abbes, C., Arroyo, S., Denney, W.S., and Ling, L.E. (2024). Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: Results of a phase 1, placebo-controlled study. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1302714"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJMoa2314466","article-title":"Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn","volume":"391","author":"Moise","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2404-8089","article-title":"Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn","volume":"42","author":"Komatsu","year":"2025","journal-title":"Am. J. Perinatol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and Efficacy of Nipocalimab in Patients with Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e004278","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: Results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0140-6736(25)01430-8","article-title":"Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjogren\u2019s disease (DAHLIAS): A randomised, phase 2, placebo-controlled, double-blind trial","volume":"406","author":"Noaiseh","year":"2025","journal-title":"Lancet"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2026.2623948","article-title":"Nipocalimab for the treatment of moderate-to-severe Sjogren\u2019s disease: A plain language summary of the DAHLIAS study","volume":"22","author":"Noaiseh","year":"2026","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): A phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Guo, Y., Tian, X., Wang, X., and Xiao, Z. (2018). Adverse Effects of Immunoglobulin Therapy. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01299"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Li, Z., Zhang, Q., Liu, X., and Zhao, M. (2022). Recombinant Humanized IgG1 Antibody Promotes Reverse Cholesterol Transport through FcRn-ERK1\/2-PPARalpha Pathway in Hepatocytes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314607"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Ward, E.S., Gelinas, D., Dreesen, E., Van Santbergen, J., Andersen, J.T., Silvestri, N.J., Kiss, J.E., Sleep, D., Rader, D.J., and Kastelein, J.J.P. (2022). Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.892534"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"16475","DOI":"10.1038\/s41598-019-52942-8","article-title":"Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: A propensity-matched study","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.4049\/jimmunol.1601198","article-title":"Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation","volume":"197","author":"Jackson","year":"2016","journal-title":"J. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/CIRCRESAHA.117.306044","article-title":"B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis","volume":"117","author":"Rosenfeld","year":"2015","journal-title":"Circ. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/CIRCRESAHA.121.320436","article-title":"B-1b Cells Possess Unique bHLH-Driven P62-Dependent Self-Renewal and Atheroprotection","volume":"130","author":"Pattarabanjird","year":"2022","journal-title":"Circ. Res."},{"key":"ref_211","unstructured":"(2026, March 11). Viridian Therapeutics Prepares for Transformational. Available online: https:\/\/www.biospace.com\/press-releases\/viridian-therapeutics-prepares-for-transformational-2026."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/923\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:11:38Z","timestamp":1780546298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":211,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16060923"],"URL":"https:\/\/doi.org\/10.3390\/life16060923","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}